Morningstar - H. Lundbeck A/S (LUN) Lundbecks Increased Penetration Into the U.S. Market Drives 2Q Results; Raising Our FVE

Report

Morningstar

Karen Andersen

EUR 147.86 For Business Accounts Only

Lundbeck's Increased Penetration Into the U.S. Market Drives 2Q Results; Raising Our FVE

We plan to slightly raise our fair value estimate for Lundbeck to DKK 205 per share from DKK 196 thanks to stronger-than-expected uptake of Abilify Maintena (to treat psychosis) and Rexulti (major depressive disorder, schizophrenia) released in the companyâ€™s second-quarter results. We believe the solid, persistent growth signals that Lundbeckâ€™s efforts to differentiate its central nervous system drugs in a particularly difficult space with high patient churn is paying off. As a result, we have i...

24/08/2016 12 EN

Underlying

H. Lundbeck A/S

H. Lundbeck develops, produces and markets drugs for treating diseases of the central nervous system. Products include antidepressants for the treatment of depression, panic disorder, and prevention of relapse/recurrence. Antipsychotic products for psychotic disorders; schizophrenia, anxiety, restlessness and insomnia; treatment of psychotic disorders; acute psychotic episodes, exacerbation of psychotic disorders. Co.'s products inclue Cipralex®/Lexapro® for the treatment of depression and anxiety; Ebixa® for the treatment of Alzheimer's disease; Azilect® for the treatment of Parkinson's disease; Xenazine®, Sabril®, Saphris® Sycrest®, Onfi, and other.

See profile

DK0010287234 Nasdaq Nordic Copenhagen Denmark

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

Karen Andersen

Other Reports on these Companies

DnB Markets

Lundbeck (Buy, TP: DKK44.00) - New guidance structure

Q4 sales and EBITDA missed our forecasts as strategic brands sales were soft. The 2024 guidance was also soft but in a new better structure, we believe, for revenue growth of 7–10% CER (-4% in DKK) and adj. EBITDA growth of 10–16% in CER (-9% in DKK). We also note the decision to move Lu AF82422 into phase III in MSA. We reiterate our BUY and DKK44 target price.

Free Trial

February 7, 2024 February 7, 2024 1 EN

DnB Markets

Lundbeck (Buy, TP: DKK44.00) - Focus on guidance and M&A

We expect Lundbeck to reach the high end of its 2023 guidance, and forecast Q4 revenue of DKK5,111m and adj. EBITDA of DKK929m. For 2024, we look for continued good growth across strategic brands (we forecast 12.9%), and we believe investors will focus on the M&A agenda to strengthen the late-stage pipeline. We expect the 2024 guidance to be for revenue of DKK21.0bn–21.6bn and EBITDA of DKK5.7bn–6.3bn. We reiterate our BUY and DKK44 target price.

Free Trial

January 30, 2024 January 30, 2024 1 EN

DnB Markets

Lundbeck (Buy, TP: DKK44.00) - Focus on progressing the pipeline

At Lundbeck’s R&D event in London yesterday, focus was on pipeline progression and its R&D commitment. Lundbeck believes two of the six discussed pipeline candidates could reach the market in 2029. In the coming years, we expect increased focus on acquisitions to strengthen the late-stage pipeline to facilitate timely new product launches before the ‘patent cliff’ (we estimate in 2029). We reiterate our BUY and DKK44 target price.

Free Trial

December 1, 2023 December 1, 2023 1 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Lundbeck's Increased Penetration Into the U.S. Market Drives 2Q Results; Raising Our FVE

Lundbeck (Buy, TP: DKK44.00) - New guidance structure

Lundbeck (Buy, TP: DKK44.00) - Focus on guidance and M&A

Lundbeck (Buy, TP: DKK44.00) - Focus on progressing the pipeline

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe